Esperion (ESPR) Q2 Revenue Jumps 12%

Esperion Therapeutics (NASDAQ:ESPR), a specialty pharmaceutical company focused on cardiovascular disease, delivered higher-than-expected GAAP results in its latest earnings release. On August 5, 2025, it reported results. Revenue (GAAP) was $82.4 million, well above the analyst estimate of $63.05 million (GAAP). The GAAP earnings per share (EPS) loss narrowed to $0.02, compared to the expected GAAP loss of $0.15. The company also achieved positive operating income from ongoing operations for the first time. This quarter showed solid growth in U.S. net product sales, which increased 42% year-over-year to $40.3 million (GAAP), and progress in international collaborations, supporting management’s goal of reaching sustainable profitability in early 2026. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Esperion develops and commercializes prescription medicines to lower cholesterol and reduce cardiovascular risk for patients who are unable to achieve goals on statins. The company’s two main products, NEXLETOL and NEXLIZET, are oral therapies intended for patients who need more options to control their cholesterol levels, focusing particularly on those who cannot tolerate statins.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool